Literature DB >> 7608475

Antiviral agents in hepatitis B virus transfected cell lines: inhibitory and cytotoxic effect related to time of treatment.

J Kruining1, R A Heijtink, S W Schalm.   

Abstract

The antiviral and cytotoxic effects of ara-arabinoside monophosphate, 2',3', dideoxy-cytidine, ganciclovir, 9-2(-phosphonylmethoxyethyl) adenine, 2',3'-dideoxy-3'-thiacytidine and recombinant interferon-alpha were studied using two human hepatitis B virus transfected hepatoma cell lines, HepG2 2.2.15 and HB 611. After 9 days of exposure, starting on day 3 after seeding, inhibition of extracellular HBV-DNA expressed as ID50 was in the 0.1-1.0 microM range for 2',3'-dideoxy-3'-thiacytidine and 9-2(-phosphonylmethoxyethyl) adenine and > 10 microM for dideoxy-cytidine, ara-arabinoside monophosphate and ganciclovir in both cell lines. At 2.500 U/ml recombinant interferon-alpha showed less than 20% inhibition in both cell lines. The HBV-DNA inhibitory effects of 2',3'-dideoxy-3'-thiacytidine and 9-2(-phosphonylmethoxyethyl) adenine were also investigated after 1 and 3 days of exposure. In that setting ID50's were 10 and 3.3 microM for 2',3'-dideoxy-3'-thiacytidine and > 100 and 30 microM for 9-2(-phosphonylmethoxyethyl) adenine, respectively. No major inhibitory effect on hepatitis B surface antigen and hepatitis B e antigen secretion was observed for any agent in this study, except for 9-2(-phosphonylmethoxyethyl) adenine in HB 611 cells. Cytotoxicity measured by inhibition of [3H-methyl] deoxythymidine incorporation and expressed as CD50 on day 4 was in the 10-100 microM range for ara-arabinoside monophosphate; in the 100-1000 microM range for 9-2(-phosphonylmethoxyethyl) adenine, ganciclovir and dideoxy-cytidine; and > 1000 microM for 2',3'-dideoxy-3'-thiacytidine.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7608475     DOI: 10.1016/0168-8278(95)80277-0

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  9 in total

1.  Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (-)-beta-2',3'-dideoxy-3'-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA.

Authors:  W E Delaney; T G Miller; H C Isom
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

Review 2.  Mitochondrial injury. Lessons from the fialuridine trial.

Authors:  P Honkoop; H R Scholte; R A de Man; S W Schalm
Journal:  Drug Saf       Date:  1997-07       Impact factor: 5.606

3.  Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro.

Authors:  Julien Delmas; Olivier Schorr; Catherine Jamard; Craig Gibbs; Christian Trépo; Olivier Hantz; Fabien Zoulim
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

Review 4.  Lamivudine. A review of its therapeutic potential in chronic hepatitis B.

Authors:  B Jarvis; D Faulds
Journal:  Drugs       Date:  1999-07       Impact factor: 9.546

5.  The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance.

Authors:  S K Ono; N Kato; Y Shiratori; J Kato; T Goto; R F Schinazi; F J Carrilho; M Omata
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

Review 6.  Adefovir dipivoxil: a review of its use in chronic hepatitis B.

Authors:  Toni Dando; Greg Plosker
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 7.  Targeting hepatitis B therapy to the liver. Clinical pharmacokinetic considerations.

Authors:  P C Rensen; R L de Vrueh; T J van Berkel
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

8.  Lack of effect of lamivudine on Ebola virus replication.

Authors:  Lisa E Hensley; Julie Dyall; Gene G Olinger; Peter B Jahrling
Journal:  Emerg Infect Dis       Date:  2015-03       Impact factor: 6.883

9.  Evaluation of the Activity of Lamivudine and Zidovudine against Ebola Virus.

Authors:  Yu Cong; Julie Dyall; Brit J Hart; Lisa Evans DeWald; Joshua C Johnson; Elena Postnikova; Huanying Zhou; Robin Gross; Oscar Rojas; Isis Alexander; Nicole Josleyn; Tengfei Zhang; Julia Michelotti; Krisztina Janosko; Pamela J Glass; Mike Flint; Laura K McMullan; Christina F Spiropoulou; Tim Mierzwa; Rajarshi Guha; Paul Shinn; Sam Michael; Carleen Klumpp-Thomas; Crystal McKnight; Craig Thomas; Ann E Eakin; Kathleen G O'Loughlin; Carol E Green; Paul Catz; Jon C Mirsalis; Anna N Honko; Gene G Olinger; Richard S Bennett; Michael R Holbrook; Lisa E Hensley; Peter B Jahrling
Journal:  PLoS One       Date:  2016-11-30       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.